ONCTERNAL THERAPEUTICS INC
1 day chart
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.
Buy US stocks in Australia starting with ONCT. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ONCT
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.